Trial Profile

A Randomized Placebo-Controlled Trial of the Efficacy of Preventive Dosage of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism in Patients Undergoing Coronary Artery Bypass Graft Surgery (CABG).

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fondaparinux sodium (Primary)
Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
Focus Therapeutic Use

29 Dec 2015 As per an article published in the American Heart Journal, this trial has been terminated early because of the relocation of the principal investigator to a new institution.
29 Dec 2015 Status changed from active, no longer recruiting to discontinued, as per an article published in the American Heart Journal
29 Dec 2015 Results published in the American Heart Journal

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com